Solid biosciences reports inducement grant to new chief regulatory officer

Cambridge, mass., june 07, 2021 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company focused on advancing meaningful therapies for duchenne muscular dystrophy (duchenne), today announced the grant of an inducement award to its newly appointed chief regulatory officer, dr. iman barilero. the grant was approved by a majority of the independent directors of the company on may 5, 2021 as an inducement material to dr. barilero entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4).
SLDB Ratings Summary
SLDB Quant Ranking